Cargando…

Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model

Human killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail (KIR3DL3) is expressed on natural killer (NK) cells and is a newly identified inhibitory receptor for B7 family member HERV-H LTR-associating protein 2 (HHLA2). Here, we summarize the isolation and expansion o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Xiaoxin, Corrigan, Devin T., Zang, Xingxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641272/
https://www.ncbi.nlm.nih.gov/pubmed/36386885
http://dx.doi.org/10.1016/j.xpro.2022.101818
_version_ 1784826061766262784
author Ren, Xiaoxin
Corrigan, Devin T.
Zang, Xingxing
author_facet Ren, Xiaoxin
Corrigan, Devin T.
Zang, Xingxing
author_sort Ren, Xiaoxin
collection PubMed
description Human killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail (KIR3DL3) is expressed on natural killer (NK) cells and is a newly identified inhibitory receptor for B7 family member HERV-H LTR-associating protein 2 (HHLA2). Here, we summarize the isolation and expansion of KIR3DL3(+) human NK cells, and in vitro functional characterization of in-house anti-KIR3DL3 monoclonal antibody (mAb). We also describe a human NK cell-based xenogeneic lung tumor model for testing the therapeutic activity of KIR3DL3 blockade in vivo. For complete details on the use and execution of this protocol, please refer to Wei et al. (2021).
format Online
Article
Text
id pubmed-9641272
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96412722022-11-15 Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model Ren, Xiaoxin Corrigan, Devin T. Zang, Xingxing STAR Protoc Protocol Human killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail (KIR3DL3) is expressed on natural killer (NK) cells and is a newly identified inhibitory receptor for B7 family member HERV-H LTR-associating protein 2 (HHLA2). Here, we summarize the isolation and expansion of KIR3DL3(+) human NK cells, and in vitro functional characterization of in-house anti-KIR3DL3 monoclonal antibody (mAb). We also describe a human NK cell-based xenogeneic lung tumor model for testing the therapeutic activity of KIR3DL3 blockade in vivo. For complete details on the use and execution of this protocol, please refer to Wei et al. (2021). Elsevier 2022-11-04 /pmc/articles/PMC9641272/ /pubmed/36386885 http://dx.doi.org/10.1016/j.xpro.2022.101818 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Protocol
Ren, Xiaoxin
Corrigan, Devin T.
Zang, Xingxing
Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model
title Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model
title_full Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model
title_fullStr Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model
title_full_unstemmed Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model
title_short Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model
title_sort protocol for evaluating antitumor activity of kir3dl3 blockade in an nk cell-based xenogeneic lung tumor model
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641272/
https://www.ncbi.nlm.nih.gov/pubmed/36386885
http://dx.doi.org/10.1016/j.xpro.2022.101818
work_keys_str_mv AT renxiaoxin protocolforevaluatingantitumoractivityofkir3dl3blockadeinannkcellbasedxenogeneiclungtumormodel
AT corrigandevint protocolforevaluatingantitumoractivityofkir3dl3blockadeinannkcellbasedxenogeneiclungtumormodel
AT zangxingxing protocolforevaluatingantitumoractivityofkir3dl3blockadeinannkcellbasedxenogeneiclungtumormodel